Joachim Feldwisch

4.2k total citations · 1 hit paper
66 papers, 3.3k citations indexed

About

Joachim Feldwisch is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Joachim Feldwisch has authored 66 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Radiology, Nuclear Medicine and Imaging, 25 papers in Molecular Biology and 23 papers in Oncology. Recurrent topics in Joachim Feldwisch's work include Monoclonal and Polyclonal Antibodies Research (37 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and HER2/EGFR in Cancer Research (20 papers). Joachim Feldwisch is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (37 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and HER2/EGFR in Cancer Research (20 papers). Joachim Feldwisch collaborates with scholars based in Sweden, Germany and United States. Joachim Feldwisch's co-authors include Vladimir Tolmachev, Anders Wennborg, Anna Orlova, Lars Abrahmsén, Fredrik Y. Frejd, Mattias Sandström, J. Carlsson, Shalom Stahl, John Löfblom and Henrik Lindman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Joachim Feldwisch

65 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

2010 504 citations John Löfblom, Joachim Feldwisch et al. FEBS Letters profile →

Peers

Countries citing papers authored by Joachim Feldwisch

Since Specialization

Citations

This map shows the geographic impact of Joachim Feldwisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Feldwisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Feldwisch more than expected).

Fields of papers citing papers by Joachim Feldwisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Feldwisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Feldwisch. The network helps show where Joachim Feldwisch may publish in the future.

Co-authorship network of co-authors of Joachim Feldwisch

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Feldwisch. A scholar is included among the top collaborators of Joachim Feldwisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Feldwisch. Joachim Feldwisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study 2025 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Philip J. Mease, Kurt de Vlam, Shephard Mpofu, (unknown), Anne M. Stevens, Brian L. Wiens, (unknown), S. Ohlman, Joachim Feldwisch, Fredrik Y. Frejd, Nikolai C. Brun, (unknown), Edit Drescher, Eva Dokoupilová, (unknown), (unknown), Frank Behrens	2
2	Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy 2024 ·Biomedicines ·Nina Eißler, Renske Altena, (unknown), Olga Bragina, Joachim Feldwisch, (unknown), (unknown), Nikolai C. Brun, Rimma Axelsson, Vladimir Tolmachev, Jens Sørensen, Fredrik Y. Frejd	12
3	First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas 2024 ·Molecular Cancer Therapeutics ·Kimberley S. Samkoe, (unknown), Jason R. Gunn, Jonathan T. Elliott, (unknown), Joachim Feldwisch, Brian W. Pogue, Konstantinos Linos, Keith D. Paulsen, Eric R. Henderson	4
4	[⁶⁸Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease. 2024 ·Journal of Clinical Oncology ·(unknown), Henrik Lindman, Per Liss, Fredrik Y. Frejd, Joachim Feldwisch, Nikolai C. Brun, Mark Lubberink, Irina Velikyan, Jens Benn Sørensen	1
5	Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment 2023 ·British Journal of Dermatology ·Sascha Gerdes, Petra Staubach, Thomas Dirschka, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Joachim Feldwisch, (unknown), S. Ohlman, Paul M. Peloso, Nikolai C. Brun, Fredrik Y. Frejd	16
6	Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer 2023 ·EJNMMI Radiopharmacy and Chemistry ·(unknown), (unknown), Mohammad Mahdi Moein, (unknown), (unknown), Klas Bratteby, Erik Samén, Joachim Feldwisch, Renske Altena, Rimma Axelsson, Thuy Tran	3
7	Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis 2023 ·mAbs ·(unknown), Joachim Feldwisch, Lindvi Gudmundsdotter, (unknown), Elin Gunneriusson, (unknown), Anders Wennborg, Andrew C. Nyborg, Amol P. Kamboj, Paul M. Peloso, (unknown), Fredrik Y. Frejd	35
8	[68Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport 2020 ·EJNMMI Research ·(unknown), Frank Leigh Lu, (unknown), (unknown), Fabian Arnberg, (unknown), Anders Wennborg, Staffan Holmin, Joachim Feldwisch, Sharon Stone‐Elander	10
9	Perspectives on the phase 0 clinical trial of microdose administration of ABY-029 for fluorescence guided surgery: stability testing 2020 ·PubMed ·Kimberley S. Samkoe, (unknown), Jonathan T. Elliott, (unknown), Jason R. Gunn, Konstantinos Linos, Laura J. Tafe, Brent T. Harris, Joachim Feldwisch, Brian W. Pogue, David A. Roberts, Eric R. Henderson, Joseph A. Paydarfar, Keith D. Paulsen	4
10	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·Dan Sandberg, Vladimir Tolmachev, Irina Velikyan, Helena Olofsson, Anders Wennborg, Joachim Feldwisch, Jörgen Carlsson, Henrik Lindman, Jens Sørensen	44
11	Vision 20/20: Molecular‐guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention 2016 ·Medical Physics ·Brian W. Pogue, Keith D. Paulsen, Kimberley S. Samkoe, Jonathan T. Elliott, Tayyaba Hasan, Theresa V. Strong, Daniel R. Draney, Joachim Feldwisch	10
12	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸Ga]ABY-025 Affibody PET/CT 2015 ·Theranostics ·Jens Nørkær Sørensen, Irina Velikyan, Dan Sandberg, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Anna Orlova, Mattias Sandström, Mark Lubberink, Helena Olofsson, Jörgen Carlsson, Henrik Lindman	215
13	GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination : first-in-man 2014 ·European Journal of Nuclear Medicine and Molecular Imaging ·Irina Velikyan, Anders Wennborg, Joachim Feldwisch, Anna Orlova, Vladimir Tolmachev, Mark Lubberink, Mattias Sandström, Henrik Lindman, Jörgen Carlsson, Jens Christian Hedemann Sørensen	3
14	Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT 2014 ·European Journal of Nuclear Medicine and Molecular Imaging ·Jens Nørkær Sørensen, Irina Velikyan, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Dan Sandberg, Greger Nilsson, (unknown), Mattias Sandström, Mark Lubberink, Jörgen Carlsson, Henrik Lindman	3
15	Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold 2010 ·Journal of Nuclear Medicine ·Sara Ahlgren, Anna Orlova, Helena Wållberg, (unknown), Mattias Sandström, (unknown), Anders Wennborg, Lars Abrahmsén, Vladimir Tolmachev, Joachim Feldwisch	73
16	Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications breakdown → 2010 ·FEBS Letters ·John Löfblom, Joachim Feldwisch, Vladimir Tolmachev, J. Carlsson, Shalom Stahl, Fredrik Y. Frejd	504
17	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules 2009 ·Bioorganic & Medicinal Chemistry Letters ·T. Ekblad, Anna Orlova, Joachim Feldwisch, Anders Wennborg, Amelie Eriksson Karlström, Vladimir Tolmachev	14
18	Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of ^99mTc-Labeled Anti-HER2 Affibody Molecules 2008 ·Bioconjugate Chemistry ·Thuy Tran, T. Ekblad, Anna Orlova, Mattias Sandström, Joachim Feldwisch, Anders Wennborg, Lars Abrahmsén, Vladimir Tolmachev, Amelie Eriksson Karlström	42
19	Synthesis of technetium-chelating affibody molecules for diagnostic imaging of HER2-expressing tumours 2006 ·Journal of Peptide Science ·Torun Engfeldt, Thuy Tran, Anna Orlova, Charles Widström, Joachim Feldwisch, (unknown), Anders Wennborg, Amelie Eriksson Karlström, Vladimir Tolmachev	1
20	Identification and Characterization of a Novel Phytohormone Conjugate Specific Beta-Glucosidase Activity from Maize 1993 ·MPG.PuRe (Max Planck Society) ·Nádia Alves Campos, László Bakó, Břetislav Brzobohatý, Joachim Feldwisch, Rolf Zettl, Wilhelm Boland, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact